I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claims 7-11, 17-20, and 25-30 without prejudice to renewal.

1.-11. (Cancelled)

12. (Previously presented) A method of screening for biologically active agents that modulate a phenomenon associated with Alzheimer's disease (AD), the method comprising:

(a) contacting a cell that produces a neurotoxic, hydrophobic, lipid-binding, carboxyl-terminal truncated apolipoprotein E (apoE) polypeptide with a test agent, wherein the neurotoxic carboxyl-terminal truncated apoE polypeptide comprises amino acids 244-260 of apoE; and

(b) determining the effect of said agent on the level of the carboxyl-terminal apoE polypeptide in the cell, wherein an agent that reduces the level of the carboxyl-terminal truncated apoE polypeptide is a candidate agent for modulating a phenomenon associated with AD.

13. (Previously presented) The method of claim 12, wherein the cell is a cell in a non-human transgenic animal that comprises, as a transgene, a nucleic acid that comprises a nucleotide sequence encoding apoE.

14. (Original) The method of claim 12, wherein the cell is an *in vitro* cell.

15.-31. (Cancelled)

32. (Previously presented) The method of claim 14, wherein the cell comprises a nucleic acid that comprises a nucleotide sequence that encodes the carboxyl-terminal truncated form of apoE.

33. (Previously presented) The method of claim 12, wherein the apoE is apoE4.

34. (Previously presented) The method of claim 33, wherein the carboxyl-terminal truncated form of apoE4 is apoE4(Δ272-299).

35. (Previously presented) The method of claim 14, wherein the cell is a neuronal cell.

36.-37. (Cancelled)